Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SEA-CD70 in Myeloid Malignancies
NCT04227847Phase 1Active, not recruiting
- Sponsor
- Pfizer
- Start
- Aug 2020
- Primary completion
- Jul 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label trial of SEA-CD70 in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) (7 arms), sponsored by Pfizer. Primary endpoints: Adverse Events up to 2 years, Laboratory abnormalities up to 2 years and 1 more. Started Aug 2020; status: active, not recruiting.
02
Drugs
SEA-CD70
03
Conditions
myelodysplastic syndrome (MDS)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04227847.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04227847.